期刊
JOURNAL OF UROLOGY
卷 182, 期 6, 页码 2569-2577出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1016/j.juro.2009.08.085
关键词
kidney; carcinoma, renal cell; D 21266; 1-phosphatidylinositol 3-kinase; mTOR protein
Purpose: The P13K/Akt signaling pathway is activated by many cellular stimuli. It regulates fundamental cellular functions, including transcription, translation, proliferation, growth and survival. It also closely interacts with many other key pathways such as mTOR and, thus, is linked to angiogenesis. Disturbed activation of the P13K/Akt pathway is associated with many human malignancies. We reviewed the available literature on P13K/Akt and P13KJAkt targeting drugs for renal cell carcinoma. Materials and Methods: MEDLINEO and the proceedings of the main oncological meetings were extensively searched to identify the available literature on the role of this pathway in renal cell carcinoma pathogenesis, and on preclinical and clinical activity of compounds specifically targeting this pathway. Clinical data and perspectives on several compounds at different stages of development were also reviewed. Results: Cumulative evidence links P13K/Akt alterations with renal cell carcinoma. Thus, renal cell carcinoma is an ideal setting in which to test compounds specifically targeting this pathway. Several P13KJAkt inhibitors are currently under preclinical and early clinical development as anticancer agents but only perifosine (Keryx Biopharmaceuticals, New York, New York) appears to be at a more advanced stage, having been tested with promising results alone or combined with other molecularly targeted agents. Conclusions: The P13Y/Akt pathway has a pivotal role in renal cell carcinoma pathogenesis and, thus, represents an ideal target for therapeutic intervention. Of the several compounds in early phases of development only perifosine has already proved to be clinically active. Thus, it should be considered an extremely interesting drug to be used alone or in combination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据